<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905459</url>
  </required_header>
  <id_info>
    <org_study_id>101703</org_study_id>
    <nct_id>NCT04905459</nct_id>
  </id_info>
  <brief_title>ARDA Software for the Detection of mtmDR</brief_title>
  <official_title>A Multicenter Study to Evaluate the Performance of Automated Retinal Disease Assessment Software for the Detection of More Than Mild Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verily Life Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Google LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Optos, PLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nikon Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Verily Life Sciences LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, observational study with primary endpoints to determine the&#xD;
      sensitivity and specificity of two investigational software devices that detect the presence&#xD;
      of more than mild diabetic retinopathy (mtmDR) in healthcare settings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of ARDA mtmDR for detection of mtmDR in 45 degree images</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of ARDA mtmDR for detection of mtmDR in 45 degree images</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of ARDA mtmDR for detection of mtmDR in UWF images</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of ARDA mtmDR for detection of mtmDR in UWF images</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1008</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Retinal Imaging and Mydriatic Agents</arm_group_label>
    <description>Subjects will undergo several types of retinal imaging before and after administration of mydriatic agent. Subjects will be administered mydriatic medication to dilate their pupils.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ARDA software application</intervention_name>
    <description>Subject images will be sent to the investigational ARDA software</description>
    <arm_group_label>Retinal Imaging and Mydriatic Agents</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sites in the U.S.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of Type I or Type II diabetes mellitus:&#xD;
&#xD;
             meet the criteria established by either the World Health Organization (WHO) or the&#xD;
             American Diabetes Association (ADA)&#xD;
&#xD;
          2. Age 22 or older&#xD;
&#xD;
          3. Understand the study and volunteer to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Self-reported visual symptoms and persistent blurred vision (greater than 24 hours);&#xD;
             including vision loss that cannot be corrected (e.g. with eye glasses).&#xD;
&#xD;
          2. Diagnosed with macular edema, any known retinopathy, radiation retinopathy, or retinal&#xD;
             vein occlusion.&#xD;
&#xD;
          3. History of laser treatment of the retina or injections into either eye, or any history&#xD;
             of retinal surgery.&#xD;
&#xD;
          4. Scheduled to undergo the following surgeries before completion of the study imaging:&#xD;
             cataract surgery (including any related follow-up procedures) or vitrectomy.&#xD;
&#xD;
          5. Currently participating in an interventional study.&#xD;
&#xD;
          6. Participant has a condition that, in the opinion of the investigator, would preclude&#xD;
             participation in the study (e.g., unstable medical status including blood pressure or&#xD;
             glycemic control, microphthalmia or previous enucleation, etc.).&#xD;
&#xD;
          7. Participant is contraindicated for imaging by fundus imaging system used in the study;&#xD;
             e.g.&#xD;
&#xD;
               1. Participant is hypersensitive to light (side effect of medication or due to&#xD;
                  unknown etiology)&#xD;
&#xD;
               2. Participant has undergone photodynamic therapy (PDT)&#xD;
&#xD;
               3. Previous issues with dilation (angle closure, inability to dilate, allergy to&#xD;
                  dilation drops).&#xD;
&#xD;
          8. Known pregnancy or possibility of pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Han</last_name>
    <phone>6508142278</phone>
    <email>jenniferhan@verily.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nilay Shah</last_name>
    <email>arda@emmes.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

